Details of the Drug

General Information of Drug (ID: DMRGZ16)

Drug Name

Sulfamethazine

Synonyms

Azolmetazin; Cremomethazine; Diazil; Dimezathine; Intradine; Kelametazine; Mermeth; Neasina; Neazina; Pirmazin; Primazin; Solfadimidina; Spanbolet; Sulfadimerazine; Sulfadimesin; Sulfadimesine; Sulfadimethyldiazine; Sulfadimethylpyrimidine; Sulfadimezin; Sulfadimezine; Sulfadimezinum; Sulfadimidin; Sulfadimidina; Sulfadimidine; Sulfadimidinum; Sulfadine; Sulfametazina; Sulfametazyny; Sulfamethiazine; Sulfamezathine; Sulfodimesin; Sulfodimezine; Sulphadimethylpyrimidine; Sulphadimidine; Sulphamethasine; Sulphamethazine; Sulphamezathine; Sulphamidine; Sulphodimezine; Superseptil; Superseptyl; Vertolan; Calfspan Tablets; Sa III; Solfadimidina [DCIT]; SulfaSURE SR Bolus; Sulfadimidine solution; Sulfametazina[Italian]; Sulfametazyny [Polish]; Sulfamethazine solution; Sulka S Boluses; BN 2409; HC210279; A-502; Diazil (the sulfanilamide); Dimidin-R; Hava-Span; Sulfa-Isodimerazine; Sulfadimidina [INN-Spanish]; Sulfadimidine (INN); Sulfadimidine [INN:BAN]; Sulfadimidinum [INN-Latin]; Sulfamethazine (USP); Sulfamezathine (TN); N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 4,6-Dimethylsulfadiazine; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; 4-Amino-N-[4,6-dimethyl-2-pyrimidinyl]-benzenesulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

278.33

Logarithm of the Partition Coefficient (xlogp)

0.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The drug is rapidly absorbed following oral administration []
Bioavailability: 86.5% of drug becomes completely available to its intended biological destination(s) [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 153.9796 micromolar/kg/day [3]

Chemical Identifiers

Formula: C12H14N4O2S
IUPAC Name: 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
Canonical SMILES: CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
InChI: InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)
InChIKey: ASWVTGNCAZCNNR-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5327
ChEBI ID: CHEBI:102265
CAS Number: 57-68-1
DrugBank ID: DB01582
TTD ID: D0V9YR
VARIDT ID: DR01210

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Biotransformations	[5]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[6]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080123.
2	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80.
5	Functional genomics of C190T single nucleotide polymorphism in human N-acetyltransferase 2. Biol Chem. 2002 Jun;383(6):983-7. doi: 10.1515/BC.2002.105.
6	CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.